Ezetimibe interactions
Full monograph for EzetimibeCheck it against another medicine
Medicines
488 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Amlodipine Besilate + Atorvastatin | Moderate | Others · Unknown | Coadministration with ezetimibe may rarely increase the risk of myopathy and serum transaminase elevations associated with HMG-CoA reductase inhibitors (i.e…2 documented mechanisms | 10 sources — open the full entry |
| Apalutamide | Moderate | Absorption · Metabolism | Coadministration with apalutamide may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4, 2C9, 2C19, breast… | 5 sources — open the full entry |
| Atorvastatin + Ezetimibe | Moderate | Others | Coadministration with ezetimibe may rarely increase the risk of myopathy and serum transaminase elevations associated with HMG-CoA reductase inhibitors (i.e… | 10 sources — open the full entry |
| Atorvastatin Calcium | Moderate | Others | Coadministration with ezetimibe may rarely increase the risk of myopathy and serum transaminase elevations associated with HMG-CoA reductase inhibitors (i.e… | 10 sources — open the full entry |
| Cyclosporine (Oral) | Moderate | Others | Coadministration with cyclosporine may significantly increase the plasma concentrations of ezetimibe. The mechanism of interaction is unknown. | 15 sources — open the full entry |
| Darolutamide | Moderate | Metabolism | Coadministration with darolutamide may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptides (OATP)… | 4 sources — open the full entry |
| Eltrombopag Olamine | Moderate | Metabolism | Coadministration with eltrombopag may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide (OATP) 1B1… | 7 sources — open the full entry |
| Eluxadoline | Moderate | Others | Coadministration with eluxadoline may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide (OATP) 1B1… | 11 sources — open the full entry |
| Enasidenib | Moderate | Distribution | Based on in vitro data, coadministration with enasidenib may increase the plasma concentrations of drugs that are substrates of the transporters, organic anion… | 3 sources — open the full entry |
| Fenofibrate | Moderate | Synergy | Concomitant use of ezetimibe may potentiate the risk of cholelithiasis associated with fenofibrate and other fibrates. Fibrates can increase cholesterol… | 1 sources — open the full entry |
| Fluvastatin | Moderate | Others | Coadministration with ezetimibe may rarely increase the risk of myopathy and serum transaminase elevations associated with HMG-CoA reductase inhibitors (i.e… | 10 sources — open the full entry |
| Gemfibrozil | Moderate | Others | The safety and efficacy of ezetimibe coadministered with fibrates other than fenofibrate have not been studied. Fibrates can increase cholesterol excretion… | 1 sources — open the full entry |
| Pitavastatin Calcium | Moderate | Others | Coadministration with ezetimibe may rarely increase the risk of myopathy and serum transaminase elevations associated with HMG-CoA reductase inhibitors (i.e… | 10 sources — open the full entry |
| Pravastatin Sodium | Moderate | Others | Coadministration with ezetimibe may rarely increase the risk of myopathy and serum transaminase elevations associated with HMG-CoA reductase inhibitors (i.e… | 10 sources — open the full entry |
| Rosuvastatin + Ezetimibe | Moderate | Others | Coadministration with ezetimibe may rarely increase the risk of myopathy and serum transaminase elevations associated with HMG-CoA reductase inhibitors (i.e… | 10 sources — open the full entry |
| Rosuvastatin Calcium | Moderate | Others | Coadministration with ezetimibe may rarely increase the risk of myopathy and serum transaminase elevations associated with HMG-CoA reductase inhibitors (i.e… | 10 sources — open the full entry |
| Simvastatin | Moderate | Others | Coadministration with ezetimibe may rarely increase the risk of myopathy and serum transaminase elevations associated with HMG-CoA reductase inhibitors (i.e… | 10 sources — open the full entry |
| Zavegepant | Moderate | Excretion · Metabolism | Coadministration with inhibitors of the organic anion transporting polypeptide (OATP) 1B3 hepatic uptake transporter and/or the hepatic bile acid uptake… | 4 sources — open the full entry |
| Warfarin Sodium | Minor | Others | In a study of 12 healthy adult males, coadministration of ezetimibe (10 mg once daily) had no significant effect on the bioavailability of warfarin or… | 38 sources — open the full entry |
Conditions
Conditions in which Ezetimibe needs care, as documented in this source.
Liver Diseases
MajorEzetimibe is partially metabolized in the liver. After a single 10 mg dose, the mean area under the plasma concentration-time curve (AUC) for total ezetimibe was increased approximately 1.7-fold, 3- to 4-fold, and 5- to 6-fold, in patients with mild (Child-Pugh score 5 to 6), moderate (Child-Pugh score 7 to 9), and severe hepatic impairment (Child-Pugh score 10 to 15), respectively, compared to healthy subjects. Due to the unknown effects of increased exposure to ezetimibe in patients with moderate or severe hepatic impairment, therapy with ezetimibe is not recommended in these patients. The combination of ezetimibe with a statin is contraindicated in patients with active liver disease or unexplained persistent elevations in hepatic transaminase levels.
1 source
- "Product Information. Zetia (ezetimibe)." Schering-Plough Corporation (2002):
Kidney Diseases
ModerateNo dosage adjustment of ezetimibe is necessary in patients with renal impairment. However, when ezetimibe therapy is given in combination with simvastatin in patients with moderate to severe renal impairment (estimated glomerular filtration rate <60 mL/min/1.73 m2), doses of simvastatin exceeding 20 mg should be used with caution and close monitoring is recommended.
1 source
- "Product Information. Zetia (ezetimibe)." Schering-Plough Corporation (2002):
Rhabdomyolysis
ModerateMyopathy and rhabdomyolysis are known adverse reactions to statins and other lipid-lowering drugs. In post-marketing experience with ezetimibe, cases of myopathy and rhabdomyolysis have been reported. Most patients who developed rhabdomyolysis were taking a statin prior to initiating ezetimibe. However, rhabdomyolysis has been reported with ezetimibe monotherapy and with the addition of ezetimibe to agents known to be associated with increased risk of rhabdomyolysis, such as fibrates. In the presence of muscle symptoms and a CPK level >10 × the ULN indicative of myopathy, ezetimibe and any statin or fibrate that the patient is taking concomitantly should be immediately discontinued if myopathy is diagnosed or suspected.
1 source
- "Product Information. Zetia (ezetimibe)." Schering-Plough Corporation (2002):